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1. Introduction 
The incidence of pancreatic carcinoma varies from 6-20/100.000 in different countries and 
ethnic groups, but is considered to be on the average 10/100.000 (Gudjonsson 1987) and 
causes a significant economic burden on health resources (Gudjonsson 1995, Du 2000). 
Cancer of the pancreas is the 13th in frequency in the USA but fourth most frequent cause of 
death from cancer (Jemal 2010) fifth most frequent cause of death in Japan and sixth in 
China. 
Adenocarcinoma constitutes 90% of pancreatic malignancies. Only 50% of patients in tumor 
registries had histologic confirmation (Gudjonsson 1987). 
The cause of pancreatic cancer is unclear but it is more frequent among cigarette smokers. 
Chronic pancreatitis leads to increased frequency. 
2. Genes 
Mutations in K-ras genes are found in up to 90% of cases of cancer of the pancreas but are 
not specific and are also found in patients with chronic pancreatitis. The suppressor genes 
p16 and p53 are inactivated and DPC4 deleted in 50% of cases of pancreatic cancer. (Cowgill 
2003). 
3. Clinical features 
The disease is slightly more frequent among males than females. 
Patients may occasionally be under thirty years of age. Forty percent are between 60-70 
years. Thirty percent are between 50-60 years old and twenty percent between 70-80 years 
old (Gudjonsson 1987). 
4. Clinical features 
Majority of patients complain of weight loss which is on the average 10 kg. Most complain 
of pain, which may be deep seated, in a third of patients the pain radiates to the back, a fifth 
experience relief by bending forward, and 10-15% it is worsened with eating. 
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Anorexia may be present in half of patients. A third may complain of vomiting. A third 
complain of acholic stools and dark urine. One in four may report jaundice (Gudjonsson 
1987).  
 
Fig. 1. Age distribution. 
Duration of symptoms is variable but 40% have had symptoms less than 1 month, 20% 2 
months and 10% 3 months. 
 
Fig. 2. Duration of symptons. 
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5. Physical findings 
Hepatomegaly may be present in over 50% of patients, 40% may have clinical jaundice, 
blood in stool may be found in one in four, abdominal mass found in one in five and ascites 
in more than one in ten. 
6. Laboratory values 
Elevated alkaline phosfatase and gamma GT are the most frequent abnormalities or in close 
to 80% of patients, while 60% have elevated SGOT. 
Fasting hyperglycemia may be found in close to 60% of patients. Hyperbilirubinemia is 
initially found in approximately 50%, anemia and elevated lipase in a third.  
CA 19-9 may be elevated in 80-90% but is mainly of benefit in monitoring the progress of the 
disease. 
7. Differential diagnosis 
The main differential diagnosis are gastric pathology, i.e. cancer or ulcers, gallstones, 
chronic pancreatitis, or ampullary ca. 
 
Fig. 3. CT. Pancreatic cancer. Axial view. 
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Fig. 4. CT. Pancreatic cancer, Sagital view. Metastases in liver. 
8. Diagnostic procedure 
In non-jaundice patients it is appropriate to start with upper endoscopy or radiographic 
upper gastrointestinal studies. In a jaundiced patient ultrasound would establish or rule out 
gallstones, but also make large tumors and liver metastases obvious. Computerised 
Tomography, especially the helical form would best confirm the extent of tumor mass and 
growth beyond the boundaries of the gland. MRI, EUS or ERCP would further delineate the 
extent of the disease. Angiography and a PET scan are of lesser value (Bipat 2005). 
Attempts should be made to obtain tissue diagnosis from the tumour mass or liver by Fine 
Needle Biopsy guided by CT, US or EUS. 
9. Prognosis, statistics 
Before doctors embark on attempts at vigorous curative therapy the documented course of 
this disease and survival statistics so far should be borne in mind (Gudjonsson 1987, 1995). 
In 90% of cases it has been found that the disease has progressed beyond the boundaries of 
the gland to adjacent lymph nodes, liver, omentum, stomach or duodenum. 
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Fig. 5. Survival distribution. 
Overall five-year survival is well below 1%. Close to 50% of patients with pancreatic 
adenocarcinoma will be dead within approximately 3 months, 65-70% within 6 months and 
85-90% within 12 months, but an occasional patient may still survive 5 years with or without 
resection. 
 
Fig. 6. Survival curve. 
The disease will cause pain and obstruction of the biliary and/or gastroduodenal system. 
A full 90% of patients will therefore primarily need palliation in the form of relief of pain 
and relief of the obstruction of the biliary and gastroduodenal system which may occur. 
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10. Operative findings 
Earlier on approximately 80% of patients would have had a surgical laparotomy after 
imaging studies and in a third of those only a biopsy would have been feasible. Half of those 
operated on would have had a biliary bypass performed and some of those also a gastric 
bypass with 5-10% undergoing only a gastric bypass (Brooks 1976). 
Now laparoscopy is increasingly used to stage the extent of disease and obtain a biopsy 
(Nagorney 1999). Either method would reveal that in 2/3 of established cases the tumor 
would be located in the head of the pancreas and one third in the body and/or tail and have 
progressed beyond the boundaries of the pancreas. Only about 10% of patients are 
resectable. 
Jaundice will be a significant problem in these patients as the disease progresses. Advances 
in endoscopic palliative therapy have been significant and stents can now be inserted by 
skilled hands endoscopically or transhepatically in the biliary system but are associated with 
complications and primarily have role in those patients who have a short term prognosis 
(Costamagna 2004). 
Many patients will still have laparotomy but are then found to be unresectable. A surgical 
biliary bypass is then advisable and an operative bypass of the hepatic or common duct is 
preferred over the gallbladder (Nagorney 1999). If there is no gastric outlet obstruction at 
that stage the value of a prophylactic gastric bypass is debated but it is well documented 
that a significant number of those patients who have longer prognosis and initially have 
only a biliary bypass will later develop gastroduodenal obstruction and will need a second 
intervention (Gudjonsson 1987). 
When a gastroduodenal obstruction occurs later in patients with biliary endoscopic stents, 
operative gastrojejunostomy may be required, but progress continues in both laparoscopic 
gastrojejunostomies and also insertion of duodenal stents (Maetani 2004). 
Pain is in most cases a major problem. If a laparotomy is performed an intraoperative 
chemical neurolytic splanchnic block should be done (Lillemoe 1999). 
In non-operated patients progress is being made in performing percutaneous, transthoracic 
(thoracoscopic) splanchnicectomy and endoscopic ultrasonographic splanchnic plexus 
blocks. 
The value of a laparotomy should not be underestimated as by then biopsy, biliary-, 
gastroduodenalbypass and splanchnic resection can be accomplished (Mann 2009). 
Resection is claimed by many to be the only chance of “cure”, but is only applicable in 10% 
of cases. Survival statistics based only on resected patients with actuarial methods and 
significant censoring are misleading (Yeo 1995, Gudjonssn 2009). 
Resections were initially fraught with a high mortality rate but that has certainly decreased 
at the relatively few centres with high volume, though morbidity is still high.  
The poor results of resections is not surprising considering that even in those who are 
considered resectable, 20-50% of resection margins are positive for cancer (Willet 1993) and 
nodes are positive in up to 80% of cases and tumor cells can be found in the bone marrow in 
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up to 50% of cases (Z’graggen 2001). Biopsy proof should be mandatory before resections 
are performed. Radical cancer surgery of 6-10 hours duration for chronic pancreatitis is not 
justified.  
An occasional resected patient may certainly survive 5 years but will then most likely be 
reported over and over in the literature (Gudjonsson 2009). 
Half of those who survive 5 years after resections have recurrence of cancer (Conlon 1996). 
The post op course of resected patients is not smooth and they may need many 
readmissions to hospitals (Gudjonsson 1995, Reddy 2009). The value of resections as 
palliation is unproven.  
True cure of pancreatic cancer after resection is exceptional.  
11. Chemotherapy 
Cancer of the pancreas is a very chemoresistant disease. Gemcitabine and 5 fluoruracil have 
been used in different forms in numerous trials of resected and nonresected patients and 
may add to quality of life and prolong life and exceptionally contribute to 5-year survival 
(Neoptolemos 2004). 
Radiation therapy has been used pre- intra- and postoperatively in various forms alone or in 
conjunction with chemotherapy but has not had any significant effect on survival. 
Novel diagnostic and therapeutic approach is needed (Yokoyama 2009). 
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